Our Science
Science & Innovation
Hua Medicine is pioneering in innovative research in basic science and translational medicine of whole-body glucose homeostasis, by establishing the concept of "repairing the sensor and restoring the homeostasis" in treatment of Type 2 diabetes (T2D). We have successfully developed dorzagliatin (a.k.a. HMS5552), an oral antidiabetic treatment which has been demonstrated in T2D patients to effectively improve the automatic control of blood glucose as well as the disposition index (DI).
As an allosteric activator of glucokinase (GK), the principal glucose sensor in human body, dorzagliatin is able to restore the compromised GK activity and repair its functional deficits in T2D patients. Dorzagliatin improves or even normalizes the glucose-stimulated insulin release (GSIR) threshold, ameliorates glucose tolerance and insulin sensitivity, and refines the dynamics of hormone secretion for both insulin and glucagon, resulting in metabolic remodeling of whole-body glucose homeostasis with a great potential to slow down the disease progression of T2D and diabetic complication by addressing the underlying cause of the disease pathophysiology.
Two Phase III registration trials for dorzagliatin monotherapy and the combination of dorzagliatin and metformin have been completed in China, as well as studies on drug mechanism synergy with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor).
We are also developing mGluR5 negative allosteric modulators (NAM) as potential novel treatment for levodopa-induced dyskinesia in Parkinson’s disease (PD-LID) and plan to initiate clinical studies in the near future.
“VIC + Q” Model and “PPR + Q” Model
Computers in pharmaceutical R&D
PK/PD modeling
Computer simulation of PK / PD model to assist experimental design and drug metrology selection, greatly improving experimental efficiency
Computer assisted T2DM precision medicine
By analyzing and mining clinical information, genotypes, and complications of Chinese patients with type 2 diabetes, and using technologies such as artificial intelligence to analyze big data, we have achieved subgrouping of patients with type 2 diabetes. Subgrouping can effectively guide the personalized treatment and management of type 2 diabetes.
滬ICP備14036654號-1
滬公網(wǎng)安備 31011502013809號 Privacy Statement Terms of Use
